Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

RenovoRx (RNXT) Cost of Revenue (2025)

RenovoRx (RNXT) has disclosed Cost of Revenue for 1 consecutive years, with $28000.0 as the latest value for Q4 2025.

  • Quarterly Cost of Revenue changed N/A to $28000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $327000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $327000.0 for FY2025, N/A changed from the prior year.
  • Cost of Revenue hit $28000.0 in Q4 2025 for RenovoRx, down from $53000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $152000.0 in Q2 2025 to a low of $28000.0 in Q4 2025.